Biogen
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrop
Basic Information
- Category: Healthcare
- Founded: 1978
- Headquarters: Cambridge, MA
- Website: https://www.biogen.com
Documented Facts
- Founded: 1978 (No linked source recorded for this statement.)
- Headquarters: Cambridge, MA (No linked source recorded for this statement.)
- Category: Healthcare (No linked source recorded for this statement.)
- Country: American (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: DE (No linked source recorded for this statement.)
- Stock ticker: BIIB (Nasdaq) (No linked source recorded for this statement.)
Products and Services
- Biogen Products: Biotechnology company focusing on neurological diseases.
Evidence and Sources
- Official Website (Primary Source)
- Biogen on instagram (social)
- Biogen on facebook (social)
- Biogen on linkedin (social)
- Biogen — Wikipedia (reference)
- BIOGEN INC. — SEC EDGAR (reference)
Citation Guidance
Explore Healthcare profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Biogen.
- Canonical profile: https://brandsource.ai/brands/biogen
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/biogen/json-ld
- Citation profile API: https://brandsource.ai/api/brands/biogen/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (82/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-01
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrop
Available profile information
- Official website is captured for entity disambiguation.
- 6 supporting sources linked.
- 7 structured facts available for extraction.
- 1 product or service signal captured.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.